Navigation Links
NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
Date:1/7/2009

Cambridge, MA January 7, 2009 Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,250,369 Phase II Small Business Innovation Research Grant (SBIR) from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) to develop in vivo zebrafish assays for assessing drug effects on Cytochrome (CYP) P450s. CYP profiling, a critical step in drug development, is required by the Food and Drug Administration (FDA) for all new drug approvals.

"This grant, 'Zebrafish Cytochrome P450 Assays for Assessing Drug Metabolism and Drug Safety,' will support the Phylonix research program for assessing potential drug-to-drug interactions (DDIs) during preclinical research," commented Patricia McGrath, Phylonix President and Chief Executive Officer. "A rapid and robust whole zebrafish CYP assay, amenable to automation in multiwell plate formats, will accelerate drug metabolism and safety profiling and reduce the possibility of costly late-stage drug development failures or product market withdrawal after commercialization," she continued.

Background on the Technical Approach

Many clinically relevant drug-to-drug interactions (DDIs) are associated with inhibition and/or induction of a CYP enzyme, such as 3A4. Modification of CYP activities can profoundly affect therapeutic efficacy and lead to life-threatening toxicity. Examples of costly high-profile drug withdrawals due to CYP-related DDIs include the antihistamines terfenadine and astemizole, the antihypertensive mibefradil and statins such as cerivastatin. A validated, simple, cost-effective in vivo CYP assay will be useful for profiling drug metabolism prior to performing expensive mammalian testing. Because of their genetic and physiological similarity to humans, zebrafish have been shown to be an efficient, predictive animal model for assessing drug metabolism and drug safety.

Advantages of Zebrafish for Compound Screening

Laboratory animals are critical for defining the mechanisms of drug activity and for testing therapeutic regimens; however, only a few useful models for assessing drug metabolism have been developed. Zebrafish have several important advantages for drug screening: they are small, inexpensive to maintain, and easily bred in large numbers. Zebrafish eggs are externally fertilized and each mating produces 100-200 eggs. Single zebrafish can be maintained in fluid volumes as small as 100 microliters for the first six days of development. Chemicals can then be added directly to the fish water, permeating the intact embryos. Standard microtiter plate readers can be used for quantitation, making this format particularly attractive for high-throughput drug screening.


'/>"/>

Contact: Ed Olear
ed.olear@phylonix.com
617-441-6700
Phylonix Pharmaceuticals
Source:Eurekalert

Related biology news :

1. Life Sciences Discovery Fund awards health research program grants
2. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
3. NIST awards $24M in grants for new research facilities
4. Northwest climate change is target of $3.2M in grants to University of Oregon
5. Dunn Foundation gives Rice $3M for collaborative research grants
6. National Science Foundation grants Clemson professors award to develop nanoprobes
7. Exciting new companies at NJITs small biz incubator get 100K in grants
8. NSF, NIH award Ecology of Infectious Disease grants
9. NSF awards two grants to Stevens for nano/micro device fabrication and nano sensor development
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. Mellon grants benefit Academy specimen collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):
(Date:7/24/2017)... ... July 24, 2017 , ... ... the stock market news outlet had initiated coverage on Interpace Diagnostics. Interpace ... and identifies exposure, progression and risk analysis from specific cancers in humans. ...
(Date:7/20/2017)... ... 20, 2017 , ... Resoundant, Inc. is pleased to introduce ... the U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography ... staging liver fibrosis assessment. , “MRE:connect was created in response to an increasing ...
(Date:7/20/2017)... ... 20, 2017 , ... Litmus Health , a clinical ... advisory board. The board comprises leaders spanning business, technology, academia, and pharmaceutical research. ... of Engineering, to Chief Technology Officer. Crooks will lead strategy and development of ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corista, a leader in integrated ... Tuesday, July 25, during the Association of Pathology Chairs’ Jubilee Meeting in Washington, ... Baras, Associate Director of Pathology Informatics, will present “The Digital Pathology Experience at ...
Breaking Biology Technology: